Drug interactions
Linagliptin-metformin + Rucaparib
Severity: Minor
Linagliptin-metformin and Rucaparib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Rucaparib is a weak inhibitor of CYP3A4 and can modestly raise exposure to CYP3A4 substrates such as linagliptin. Linagliptin has a wide therapeutic margin, so a clinically important effect is unlikely. Rucaparib may also inhibit MATE1 and MATE2-K, which could raise metformin levels.
What this interaction means in plain words
Linagliptin-metformin and Rucaparib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Linagliptin-metformin belongs to Endocrine; Rucaparib belongs to Oncology.
Why it happens
Weak CYP3A4 inhibition by rucaparib may raise linagliptin exposure, and MATE transporter inhibition may reduce metformin renal elimination.
What to do
No routine dose change is needed for linagliptin. Monitor glycemic control and for metformin adverse effects such as gastrointestinal intolerance when rucaparib is started.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Linagliptin-metformin and Rucaparib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Rucaparib
- Cisapride + Rucaparib Major
- Ergotamine + Rucaparib Major
- Pimozide + Rucaparib Major
- Alfuzosin + Rucaparib Moderate
- Aripiprazole + Rucaparib Moderate
- Atorvastatin + Rucaparib Moderate
Frequently asked questions
Can I take Linagliptin-metformin with Rucaparib?
MediHelp rates the interaction as minor. Linagliptin-metformin and Rucaparib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Rucaparib is a weak inhibitor of CYP3A4 and can modestly raise exposure to CYP3A4 substrates such as linagliptin. Linagliptin has a wide therapeutic margin, so a clinically important effect is unlikely. Rucaparib may also inhibit MATE1 and MATE2-K, which could raise metformin levels.
How serious is the interaction between Linagliptin-metformin and Rucaparib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine dose change is needed for linagliptin. Monitor glycemic control and for metformin adverse effects such as gastrointestinal intolerance when rucaparib is started.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
